Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 91
Selected: 0
NCT IDTitle
NCT01567488Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
NCT01389440Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
NCT01310010Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia
NCT01692496Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
NCT02678780Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
NCT01102608Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma
NCT03980925Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
NCT00702611Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis
NCT03000374Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
NCT00083174Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
NCT07248644Immunosuppressant Discontinuation in Elderly Patients With Ulcerative Colitis And Long-term Remission
NCT03894228Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry)
NCT02841865Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
NCT03095274Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
NCT05146440Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor
NCT03985722Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
NCT06031038Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU
NCT06878664Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
NCT01562951Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
NCT03727113Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors
NCT03242382Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
NCT01564823Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease
NCT04293419Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer
NCT04595994Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
NCT01683123Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT
NCT05809830Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas
NCT05201612Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
NCT04181970Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
NCT05661188Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)
NCT07061080Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
NCT00103168Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
NCT01455051Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
NCT01742026Aspergillus PCR Early Detection in High Risk Oncohematological Patients
NCT06211543Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
NCT03415867Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease
NCT02402062A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
NCT01276379Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
NCT00909987Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum
NCT05698745Immunological Characteristics of Preclinical IBD
NCT01262482Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment
NCT00541840Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma
NCT05271773Impact of Therapeutic Intervention on Quality of Life in Patients With Ulcerative Colitis
NCT01280201Pazopanib as Single Agent in Advanced NETs
NCT00004150High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer
NCT02340949Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
NCT03753919Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
NCT01285778Vectibix for the Treatment of Anal Cancer
NCT04595266Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
NCT01493713Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
NCT03142516FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status